Table 7.

Change in eGFR [the final evaluation point^a/W0 (week 0 of the treatment period)] analyzed by the ANCOVA model

Treatment group	Number of patients	Least square mean of the difference in serum cystatin C (mg/L)		Difference in the least square mean (versus placebo) (mg/L)		P-value
		Point estimate	SE	Point estimate	SE
Placebo	34	0.877	0.025	―	―	―
120 μg	32	0.952	0.026	0.075	0.036	0.0365
240 μg	36	0.942	0.024	0.065	0.035	0.0628

^aAt Week 28 of the treatment period or when treatment was discontinued